We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
- Authors
Monk, Bradley J; Sill, Michael W; Burger, Robert A; Gray, Heidi J; Buekers, Thomas E; Roman, Lynda D
- Abstract
Vascular endothelial growth factor is a key promoter of tumor progression in cervical carcinoma. The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of bevacizumab, a recombinant humanized anti-vascular endothelial growth factor monoclonal antibody.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 7, p1069
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.18.9043